Individuals at risk for colon cancer often go undetected, until it’s too late.
The statistics are grim: colorectal cancer is the second leading cause of cancer deaths in the United States. More than 150,000 men and women are affected each year. More surprisingly, those who are diagnosed often have no family history of colon cancer, or other identifiable risk factors.
Today colonoscopy is the reliable standard for cancer identification. Regular screening can, in many cases, prevent colorectal cancer altogether. Yet, for reasons both practical and personal, colonoscopy remains underutilized. Research shows that more than half of those who should get screened, don’t.
How will our technology affect cancer screenings?
A non-invasive test could greatly simplify the screening process for colorectal cancer. Using a small probe that is inserted just inside the rectum, we envision a test that would be easily administered by a patient’s physician, identifying those patients at high risk for cancer and in need of additional follow-up.
American BioOptics believes that such a test, which would use proprietary optical technology, has the potential to be:
- No-prep, and
- Highly accurate
Where is American BioOptics in the development process?
The research team at American BioOptics is committed to innovation. Working in collaboration with Northwestern University and Evanston Northwestern Healthcare, the team has already completed and published a significant amount of early clinical work and begun product development.
Initial results show a high degree of sensitivity and specificity of this non-invasive screening test. Over the next several years, ABO will perform extensive clinical trials, which will lead to an FDA submission and eventual product commercialization.
ABO looks forward to the future, when its technology will save thousands of lives by becoming the first population-wide initial screening test for colorectal cancer.